Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q2

9273.TEDINET S100Q755
Period2022-07-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥11.2bn2022-07-01 → 2022-12-31Cons.Net sales
Revenue¥20.4bn2021-07-01 → 2022-06-30Cons.Net sales (5-year summary)
Revenue¥10.4bn2021-07-01 → 2021-12-31Cons.Net sales
Operating income¥2.2bn2022-07-01 → 2022-12-31Cons.Operating income
Operating income¥2.2bn2021-07-01 → 2021-12-31Cons.Operating income
Ordinary income¥2.2bn2022-07-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥3.8bn2021-07-01 → 2022-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.1bn2021-07-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥2.2bn2022-07-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥2.1bn2021-07-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.4bn2021-07-01 → 2022-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2021-07-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss
Net income¥1.4bn2021-07-01 → 2021-12-31Cons.Profit loss
Total assets¥27.6bnat 2022-12-31Cons.Assets
Total assets¥26.2bnat 2022-06-30Cons.Assets
Total assets¥25.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥8.1bnat 2022-12-31Cons.Liabilities
Total liabilities¥7.6bnat 2022-06-30Cons.Liabilities
Net assets / equity¥19.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥18.7bnat 2022-06-30Cons.Net assets
Net assets / equity¥17.7bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥8.9bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥9.1bnat 2022-06-30Cons.Cash and deposits
Cash & equivalents¥8.2bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥8.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥7.2bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥7.6bnat 2021-06-30dCons.Cash and cash equivalents
Operating cash flow¥518m2022-07-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.1bn2021-07-01 → 2022-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥440m2021-07-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥120m2022-07-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥477m2021-07-01 → 2022-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥264m2021-07-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥600m2022-07-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥805m2021-07-01 → 2022-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥576m2021-07-01 → 2021-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥35.192022-07-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.552021-07-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.282021-07-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.982021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio70.8%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.9%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-12-31¥22m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥8.1bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥7.2bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-12-31¥925m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥761m
—segment totalrevenue2022-07-01 → 2022-12-31¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-12-31¥11.2bn
—segment totalrevenue intersegment2022-07-01 → 2022-12-31¥925m
—segment totalsegment profit2022-07-01 → 2022-12-31¥2.1bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-12-31−¥964m
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-12-31−¥964m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-12-31¥19m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2021-07-01 → 2021-12-31¥7.4bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2021-07-01 → 2021-12-31¥6.5bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2021-07-01 → 2021-12-31¥964m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2021-07-01 → 2021-12-31¥1.3bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2021-07-01 → 2021-12-31¥3.9bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2021-07-01 → 2021-12-31¥3.9bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2021-07-01 → 2021-12-31¥862m
—segment totalrevenue2021-07-01 → 2021-12-31¥11.3bn
—segment totalrevenue external2021-07-01 → 2021-12-31¥10.4bn
—segment totalrevenue intersegment2021-07-01 → 2021-12-31¥964m
—segment totalsegment profit2021-07-01 → 2021-12-31¥2.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 499
ItemContextValueUnit
Cost of salesPrior1YTDDuration7196762000JPY
Cost of salesCurrentYTDDuration7973282000JPY
Gross profitPrior1YTDDuration3158496000JPY
Gross profitCurrentYTDDuration3193692000JPY
Selling general and administrative expensesPrior1YTDDuration991388000JPY
Selling general and administrative expensesCurrentYTDDuration1033450000JPY
Operating incomePrior1YTDDuration2167107000JPY
Operating incomeCurrentYTDDuration2160241000JPY
Interest and dividends income noiPrior1YTDDuration2372000JPY
Interest and dividends income noiCurrentYTDDuration1841000JPY
Foreign exchange gains noiPrior1YTDDuration24334000JPY
Foreign exchange gains noiCurrentYTDDuration3644000JPY
Commission fee noiPrior1YTDDuration8071000JPY
Commission fee noiCurrentYTDDuration9331000JPY
Subsidy income noiPrior1YTDDuration2566000JPY
Subsidy income noiCurrentYTDDuration－JPY
Compensation income noiPrior1YTDDuration350000JPY
Compensation income noiCurrentYTDDuration7004000JPY
Other noiPrior1YTDDuration585000JPY
Other noiCurrentYTDDuration2820000JPY
Non operating incomePrior1YTDDuration38279000JPY
Non operating incomeCurrentYTDDuration24641000JPY
Interest expenses noePrior1YTDDuration6757000JPY
Interest expenses noeCurrentYTDDuration3949000JPY
Loss on valuation of securities noePrior1YTDDuration－JPY
Loss on valuation of securities noeCurrentYTDDuration3071000JPY
Settlement package noePrior1YTDDuration16000000JPY
Settlement package noeCurrentYTDDuration－JPY
Voluntary recall related expenses noePrior1YTDDuration34953000JPY
Voluntary recall related expenses noeCurrentYTDDuration1000JPY
Other noePrior1YTDDuration1362000JPY
Other noeCurrentYTDDuration995000JPY
Non operating expensesPrior1YTDDuration59074000JPY
Non operating expensesCurrentYTDDuration8017000JPY
Ordinary incomePrior1YTDDuration2146313000JPY
Ordinary incomeCurrentYTDDuration2176866000JPY
Income before income taxesPrior1YTDDuration2146313000JPY
Income before income taxesCurrentYTDDuration2176866000JPY
Income taxes currentPrior1YTDDuration744159000JPY
Income taxes currentCurrentYTDDuration778653000JPY
Income taxes deferredPrior1YTDDuration4575000JPY
Income taxes deferredCurrentYTDDuration3868000JPY
Income taxesPrior1YTDDuration748735000JPY
Income taxesCurrentYTDDuration782522000JPY
Profit lossPrior1YTDDuration1397578000JPY
Profit lossCurrentYTDDuration1394344000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1397578000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1394344000JPY
Profit lossPrior1YTDDuration1397578000JPY
Profit lossCurrentYTDDuration1394344000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-06-30pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-07-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-07-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-07-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass